Boston Scientific Corp. Stock Plummets to New 52-Week Low of $56.18

Boston Scientific Corp. has reached a new 52-week low, with its stock price dropping to USD 56.18 on April 29, 2026. This significant decline reflects a challenging year for the company, which has seen its stock performance decrease by 26.18% over the past year. In contrast, the S&P 500 has experienced a robust gain of 28.33% during the same period, highlighting the disparity in performance between Boston Scientific and the broader market. The company operates within the retailing industry and boasts a market capitalization of approximately USD 121,935 million, categorizing it as a large-cap entity. Financial metrics indicate a price-to-earnings (P/E) ratio of 36.00, while the return on equity stands at 13.88%. Additionally, Boston Scientific maintains a debt-to-equity ratio of 0.39, suggesting a relatively conservative approach to leverage. The stock's price-to-book ratio is recorded at 5.03, reflecting its valuation in relation to its net assets. As the company navigates this period, its recent price movement underscores the current market dynamics affecting its stock performance.